
The first quality longevity company powered by a prediction markets treasury, via @Rain__Protocol | Nasdaq: ENLV
Israel
Joined January 2026
- Tweets250
- Following30
- Followers10.7K
- Likes813
Enlivex retweeted
Before @Enlivex I spent the better part of a decade on a single molecule. A long-acting growth hormone that started as early science and eventually became a therapy Pfizer took to approval in 43 countries.
What that taught me is how long the distance is between a good result in the lab and a drug a patient can actually get. Most of that distance is not science. It's the discipline to keep a program alive through every stage where it could have died.
I came to Enlivex because I wanted to do that again, with a therapy aimed at a disease far more people live with. Knowing exactly how hard the road is doesn't make me less willing to walk it. It's the reason I know it's worth walking.
Enlivex retweeted
A study published in Nature Medicine in June, led by Washington University School of Medicine in St. Louis, found that people born in the 1990s are biologically older than people born in the 1960s were at the same age.
The gap between how long people live and how long they stay healthy is not a problem that arrives at the end of life. It is arriving earlier, in generations that are not old yet.
That changes what longevity medicine is for. The work is not just about adding years. It is addressing the decline that is already showing up ahead of schedule.
Enlivex retweeted
Most drugs work by introducing something the body does not have.
Allocetra works differently. It redirects a process the body already uses.
When dying cells are cleared by the immune system, they send a signal. That signal shifts nearby macrophages out of a pro-inflammatory state and toward tissue restoration.
Allocetra is an off-the-shelf formulation of those dying cells, injected directly into the affected knee joint. The drug does not suppress inflammation systemically. It changes the inflammatory environment at the site of disease by triggering the resolution mechanism that is already embedded in the biology.
The result is not just pain relief. It is a shift in the joint microenvironment toward conditions that support repair.
That is the mechanism. It is not novel in the sense of being invented. It is novel in the sense of being applied.
Enlivex retweeted
The current standard of care for osteoarthritis is pain management. The system pays for the disease until the joint is replaced.
@Enlivex is developing Allocetra to modify the disease itself, with the aim of intervening before surgery becomes inevitable.
A patient who keeps the joint not only keeps their mobility, but they can also stay in the workforce longer.
The clinical case and the economic case are the same case.
Two new papers suggest that the vision of health care gobbling up tax revenues may not come to pass. Register for free to learn why the good news for grandchildren does not end there economist.com/finance-and-ec…
Enlivex retweeted
We have spent decades getting better at keeping people alive.
We have not gotten better at keeping them well.
According to a 2024 Mayo Clinic study, Americans now spend an average of 12.4 years at the end of their lives in poor health. The global average is 9.6 years. Both figures have been rising for two decades.
Osteoarthritis is one of the leading drivers of those years spent in poor health.
Chronic pain. Lost mobility. Functional decline.
It is a disease affecting 32 million Americans with no approved therapy that addresses the underlying mechanism.
That is what we are working on.
Enlivex retweeted
One of the most unsettling realizations you can have as a scientist is that a field has been asking the wrong question for a hundred years.
Osteoarthritis is that field. 🧵
Enlivex retweeted
Thank you to everyone who joined for the Enlivex dinner at @proofoftalk in Paris on Tuesday night.
Evenings like that come down to the people and the questions they bring, and this room brought plenty of both.
Real conversation about where a clinical-stage company and a prediction markets treasury meet, taken seriously by people who do this work themselves.
Grateful for your time and the conversation.
Enlivex retweeted
An intimate evening with leading VCs, institutional allocators, asset managers, and digital asset investors. The Curated Dinner by @Enlivex. Tuesday, June 2.
A pre-screened guest list of top investors, founders, and decision-makers shaping the next financial cycle, gathered under the candlelight just outside the Louvre Palace.
About the host:
Enlivex (Nasdaq: ENLV) is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.
A unique combination of biotech and onchain finance, brought into the same room.
We can't wait to welcome you in Paris.
Apply for the event: luma.com/fn0jzgoc
Enlivex retweeted
Rain has officially entered the global Top 3 for prediction market TVL, trailing only @Polymarket and @Kalshi, following a massive $100M liquidity injection by the Rain Foundation ahead of the World Cup.
The allocation consists of $50M in USDT and $50M in $RAIN, flowing directly into the smart contract to deeply capitalize our prediction markets, back liquidity, tighten spreads, and support high-volume trading.
For traders, this means unmatched depth and minimal slippage. For builders, it provides a highly capitalized environment to launch custom prediction apps, and for market makers, this is the ultimate signal that the liquidity and infrastructure are ready for scale.
Funds are being deployed right now. Track the live data and metrics here: dune.com/rain_predictions/ra…
Enlivex retweeted
Healthspan and wealthspan. Two words that define what we are building at Enlivex.
That is why we built our treasury strategy around prediction markets. A quality longevity mission needs an economic foundation that can carry it forward.
Thank you to @TheCryptoMavs for the conversation.
Enlivex retweeted
Joining @ScottMelker live shortly for an AMA to talk through the Enlivex 2025 earnings release and what it means for the company.
Tune in:
xitter.gq/i/spaces/1vJpPrwNQQZJE…
Enlivex retweeted
After months of hard work, we are proud to unveil the new Enlivex website, the home for everything we are building.
I have spent decades navigating the capital-intensive cycles of the life sciences. If my tenure leading PROLOR through a $590 million exit and partnering with Pfizer taught me anything, it is that breakthrough innovation must be matched by a resilient corporate structure.
The mission at Enlivex is quality longevity. Not just living longer, but moving, functioning, and living better. Allocetra targets osteoarthritis, a condition disabling 300 million people worldwide where the current standard of care is structurally failing. That mission required a financing architecture equal to it.
We chose to anchor our treasury in the RAIN protocol because of the unique capital structure we were able to engineer. By obtaining an exclusive fixed-price option for up to $918M of RAIN, we've secured a long-term foundation to fund our clinical work.
This is an innovative financing model that gives our shareholders exposure to one of the fastest-growing sectors in the world while we advance Allocetra.
You can now explore the full vision over on our new website: enlivex.com/
We have spent the last year pioneering a first-of-its-kind model at Enlivex, and today we’re unveiling its new home.
Our core mission is to restore quality of life for the 300 million people suffering from osteoarthritis. We are currently advancing Allocetra, a therapy designed to reprogram the immune system and restore quality of life.
To fund this mission, we've engineered the world's first ever prediction markets treasury.
By anchoring our reserves in the RAIN protocol, we have created an institutional-grade wrapper that gives investors direct exposure to the upside of global prediction markets.
As the forecasting industry matures, our treasury is structurally positioned to benefit from RAIN's autonomous, programmatic economics.
This provides a unique opportunity to access a dual-engine growth model: the upside of prediction markets, and the clinical milestones of a breakthrough therapy, in a single ticker.
You can now visit our new website to explore the full model:
enlivex.com/
$ENLV











